Effect of light therapy on behavioural symptoms of dementia

INTERVENTION: Intervention1: Transcranial Near‐Infrared Stimulation: The Med X1116 Rehab Console System is a professional‐grade photobiomodulation (light therapy) device used for, among other applications, transcranial near‐infrared stimulation. The setup often includes the Med X Console (often referred to as the 1100 or 1116 model series) paired with multiple Super Luminous Diode (SLD) clusters. For transcranial use, the system utilises SLD clusters often with 52 near‐infrared diodes and 9 visible red diodes delivering light at wavelengths around 870 nm. The clusters are typically placed on the scalp to treat specific cortical areas based on the 10‐20 system, often involving 12 or more sites in a single session. It is known for its 1000 mW per SLD cluster power output and its ability to treat multiple sites simultaneously. The system is used in research and clinical settings for transcranial photobiomodulation, often combined with intranasal light therapy. Control Intervention1: Treatment as usual: Behavioural and pharmacological treatment as usual. CONDITION: Health Condition 1: F028‐ Dementia in other diseases classified elsewhere PRIMARY OUTCOME: Comparison of the change in score Neuropsychyiatry Inventory between those who received transcranial near infra‐red light stimulation+treament as usual with control group along with treatment as usual.Timepoint: 1 week, 2weeks, 3 months SECONDARY OUTCOME: To compare the change in score of cognitive symptoms of Dementia between those who received transcranial near infrared stimulation with the control group.Timepoint: One and half years. To examine the predictors of response to transcranial near infrared light stimulation in patients with dementia.Timepoint: One and half years. INCLUSION CRITERIA: Patients diagnosed who met the diagnostic criteria for the multi‐psychiatric Diagnostic Standards for Dementia, Age greater than 40 years, Either Sex, Inpatient care, Are not sensitive to light.